Press Releases

Presentation available on NRx Pharmaceuticals website at https://www.nrxpharma.com/hope-therapeutics/ KEY UPDATES ARE AS FOLLOWS: NRx management is proposing to award 50% of founding shares in...

HOPE shares currently owned by NRXP with planned share dividend to existing NRXP shareholders HOPE has now completed initial manufacture of Ketamine for IV infusion and plans to file FDA New Drug...

Companies continue to work collaboratively to advance NRX-101 through registrational trials NRx remains eligible for an additional $324 million in development and sales milestones, as well as...

Companies continue to work collaboratively to advance NRX-101 in bipolar depression with suicidality Lotus notes that NRx has "achieved a significant milestone by completing enrollment for its...

HOPE Therapeutics is dedicated to bringing NRX-100 (IV Ketamine) for Suicidal Depression to patients Company to be initially owned by NRx and current NRx shareholders via a planned tax-free...